BGI Genomics Co., Ltd. (SHE: 300676)

Market Cap	17.87B
Revenue (ttm)	4.03B
Net Income (ttm)	-101.62M
Shares Out	381.35M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	0.10 (0.21%)
Ex-Dividend Date	Jul 4, 2024

Volume	2,602,199
Open	48.30
Previous Close	47.83
Day's Range	47.47 - 48.30
52-Week Range	33.00 - 56.89
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About BGI Genomics

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected wit...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 3,752
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300676

Financial Performance

In 2023, BGI Genomics's revenue was 4.35 billion, a decrease of -38.33% compared to the previous year's 7.05 billion. Earnings were 92.90 million, a decrease of -88.43%.